CN105380962B - A kind of anti-trioxypurine composition and its preparation - Google Patents
A kind of anti-trioxypurine composition and its preparation Download PDFInfo
- Publication number
- CN105380962B CN105380962B CN201510925081.0A CN201510925081A CN105380962B CN 105380962 B CN105380962 B CN 105380962B CN 201510925081 A CN201510925081 A CN 201510925081A CN 105380962 B CN105380962 B CN 105380962B
- Authority
- CN
- China
- Prior art keywords
- trioxypurine
- group
- dietary fiber
- vitamin
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to health product technology field, in particular to a kind of anti-trioxypurine composition and its preparation.The anti-trioxypurine composition includes stripped tuna extract and dietary fiber.The present invention is by after stripped tuna extract and dietary fiber composition use, and in the case where reducing dose, anti-trioxypurine effect is more preferable instead.
Description
Technical field
The present invention relates to health product technology field, in particular to a kind of anti-trioxypurine composition and its preparation.
Background technique
With the improvement of people ' s living standards with the change of eating habit, in recent years, China's hyperuricemia and gout
Disease incidence is in the trend that rises year by year.Hyperuricemia is to lead to blood urine due to purine metabolic disturbance and/or uric acid excretion disorder
Acid is more than a kind of disease of normal value, does not show any symptom clinically.And work as the case where human body is chronically at hyperuricemia
Under, uric acid is deposited in joint, soft tissue, cartilage and kidney in the form of sodium salt, is caused Human autopsy tissues lesion, is led
Induced pain wind causes serious complication, including urarthritis, gouty renal lesions, gouty kidney stone, the gouty heart
Popular name for, gouty high blood pressure etc., there are the symptoms such as arthralgia, renal colic or blood urine in patient.Therefore, how uric acid is effectively reduced
It is the main problem that Patients with Hyperuricemia and patient with gout face.
The drug for the treatment of hyperuricemia and gout mainly has Febuxostat, Allopurinol, colchicin, benzene bromine horse at present
Grand, probenecid etc..The generation of internal uric acid is related with purine metabolism, and in the final step of purine metabolism, hypoxanthine is in Huang
Xanthine is generated under the action of purine oxidoreducing enzyme (XOR), further generates uric acid, Febuxostat and Allopurinol are XOR
Inhibitor, both drugs reduce internal uric acid synthesis, it is dense to reduce uric acid by acting on the oxidizing ferment highly selectively
Degree, thus effectively treatment ventilation disease；Colchicin by lower leucocyte activity and phagocytosis and reduce lactic acid formed from
And the deposition of uric acid crystal is reduced, mitigate inflammatory reaction, and play analgesic effect；Benzbromarone and probenecid are by inhibiting renal tubule
To the active reabsorption of lithate, increases the excretion of lithate and reduce the concentration of lithate in blood, alleviate or prevent lithate
The generation of tubercle subtracts pauciarticular damage, promotes the dissolution of established lithate.Although these drugs are for treating gout all
Tool has a better effect, but certain toxic side effect is all shown in clinic, wherein the adverse reaction of Febuxostat includes liver
Dysfunction, diarrhea, headache, joint correlation are sought peace symptom and flesh bone/connective tissue symptom；The common fash of Allopurinol, diarrhea
The adverse reactions such as abdominal pain, low-heat, temporary transaminase increase or granulocyte is reduced；Colchicin has severe toxicity, and common nausea is vomitted
It spits, diarrhea, abdominal pain, gastrointestinal reaction, blood urine, oliguresis, has direct repression to marrow, causes agranulocytosis, aregeneratory
Property anaemia etc.；Benzbromarone can cause granulocyte to reduce；The adverse reactions such as the common gastrointestinal reaction of probenecid, fash, fever, for a long time
Great pain is brought to patient using these types of drug, poses a health risk, influences quality of life.Therefore, novel treatment is developed
The drug of hyperuricemia and gout, or the health care product of improvement hyperuricemia are still current pharmacy or prevention and health care research
Hot spot.
Summary of the invention
In view of this, the present invention provides a kind of anti-trioxypurine composition and its preparations.The present invention is by stripped tuna extract and meals
After eating fiber combinations use, in the case where reducing dose, anti-trioxypurine effect is more preferable instead.
In order to achieve the above-mentioned object of the invention, the present invention the following technical schemes are provided:
The present invention provides a kind of anti-trioxypurine compositions, including stripped tuna extract and dietary fiber.
Preferably, dietary fiber is inulin and/or oligofructose.
Stripped tuna extract is a kind of a kind of sea of victory peptides based on anserine, supplemented by carnosine extracted from stripped tuna
Foreign fish oligopeptide.Experiments have shown that having the function of accelerating body to exclude uric acid.Anserine be by two kinds of amino acid (Beta-alanine and
1- methyl-histidine) a kind of imidazoles dipeptides for being combined into, imidazoles dipeptides is a kind of L-Histidine association compound.Its physiology
Meaning is to buffer the proton that it is generated during the motion, while may also have and have the work for preventing that pH value is too low in muscle
With.
Inulin is deposit property polysaccharide in plant, is mainly derived from plant, it has been found that have more than 36000 kinds, including dicotyledonous plant
11 sections such as composite family, Campanulaceae, Gentianaceae in object and the Liliaceae in monocotyledon, grass tree section.Inulin molecules are about by 31
A beta-D-fructofuranose and 1~2 pyrans synanthrin residue are polymerized, and can pass through β -2,1- key connection between residue of fructose.It grinds
Studying carefully discovery inulin can be used for preventing and treating hyperuricemia.
Oligofructose is also known as fructooligosaccharide, is to pass through the fructose in β (2-1) glycosidic bond and sucrose by 1~3 fructosyl
Base junction symphysis at ketose, Nystose and sugarcane sugar etc. mixture.There are about 60-70 grams in 100 grams of dry weight jerusalem artichokes
Inulin, inulin are by linear β -2, the levulan of 1- glucosides chain link, and end is a sucrose base.
The present invention is by after stripped tuna extract and dietary fiber composition use, in the case where reducing dose, anti-trioxypurine effect
It is more preferable instead.
Preferably, the mass ratio of stripped tuna extract and dietary fiber is (5~60): (5~70).
Preferably, the mass ratio of stripped tuna extract and dietary fiber is (5~20): 60.
In some embodiments provided by the invention, the mass ratio of stripped tuna extract and dietary fiber is 5:70.
In other embodiments provided by the invention, the mass ratio of stripped tuna extract and dietary fiber is 60:5.
In other embodiments provided by the invention, the mass ratio of stripped tuna extract and dietary fiber is 1:5.
In other embodiments provided by the invention, the mass ratio of stripped tuna extract and dietary fiber is 5:60.
In other embodiments provided by the invention, the mass ratio of stripped tuna extract and dietary fiber is 10:60.
In other embodiments provided by the invention, the mass ratio of stripped tuna extract and dietary fiber is 15:60.
In other embodiments provided by the invention, the mass ratio of stripped tuna extract and dietary fiber is 20:60.
Preferably, anti-trioxypurine composition further include vitamin B, Vitwas E, citric acid, in citrate
Mixture more than one or both.
Preferably, vitamin B is vitamin B2, vitamin B6Or the above mixture of one or both of folic acid, lemon
Hydrochlorate is sodium citrate and/or potassium citrate.
Vitamin B complex has 12 kinds or more, has nine kinds by what the world unanimously generally acknowledged, is water soluble vitamin entirely, in vivo
The time of delay only has a few hours, it is necessary to supplement daily.B race is the essential nutrient of all tissues, is that food is released
The key of exoergic amount.Vitamin E (Vitamin E) is a kind of liposoluble vitamin, and it is main that hydrolysate, which is tocopherol,
One of antioxidant.It is dissolved in the organic solvents such as fat and ethyl alcohol, it is not soluble in water, heat, acid are stablized, it is unstable to alkali, it is right
Oxygen is sensitive, insensitive to heat, but Vitamin E activity is substantially reduced when frying.Tocopherol can promote sex hormone to secrete, and keep man smart
Sub- vigor and quantity increase；Increase woman's female hormone concentration, improve fecundity, prevention of miscarriage, it may also be used for prevention and treatment male
Property sterility, burn, frostbite, capillary hemorrhage, climacteric syndrome, beauty etc..Recently it has also been found that vitamin E can press down
Lipid peroxidation reaction in ocular lens body processed makes peripheral vasodilation, improves blood circulation, pre- Anti-myopic eye occurs and hair
Exhibition.Result of study shows vitamin B2, vitamin B6, folic acid and Vitwas E can effectively reduce serum uric acid level.
Citric acid, potassium citrate and sodium citrate can alkalize uric acid, promote uric acid excretion, to reduce uric acid level.
Preferably, stripped tuna extract, dietary fiber, vitamin B2, vitamin B6, folic acid, Vitwas E, lemon
The mass ratio of acid, sodium citrate and potassium citrate is (5~60): (5~70): (0.1~10): (0.1~10): (0.001~
0.01): (0.5~10): (0.1~10): (1~20): (1~20).
The present invention also provides be subjected on a kind of anti-trioxypurine health care product, including anti-trioxypurine composition of the present invention and bromatology
Auxiliary material.The anti-trioxypurine composition includes stripped tuna extract and dietary fiber, and dietary fiber is inulin and/or oligofructose.Make
To be preferred, the mass ratio of stripped tuna extract and dietary fiber is (5~60): (5~70).
In some embodiments provided by the invention, the dosage form of anti-trioxypurine health care product is tablet, capsule, pulvis or particle
Agent.
In some embodiments provided by the invention, acceptable auxiliary material is filler, disintegrating agent, adhesive in bromatology
Or mixture more than one or both of lubricant.
In some embodiments provided by the invention, anti-trioxypurine troche of health products includes anti-trioxypurine composition of the present invention, fills out
Fill agent, disintegrating agent, adhesive and lubricant.
In some embodiments provided by the invention, anti-trioxypurine troche of health products further includes coating agent.
In some embodiments provided by the invention, filler is Lactis Anhydrous.But the type of filler of the present invention is not
It is defined in this, the filler that those skilled in the art approve is within the scope of the present invention.
In some embodiments provided by the invention, disintegrating agent is crospovidone.But the type of disintegrating agent of the present invention is simultaneously
It is non-limiting in this, those skilled in the art approve disintegrating agent it is within the scope of the present invention.
In some embodiments provided by the invention, lubricant is silica and/or magnesium stearate.But the present invention lubricates
The type of agent is not limited to this, and the lubricant that those skilled in the art approve is within the scope of the present invention.
In the present invention, tablet the preparation method comprises the following steps: by citric acid, potassium citrate, sodium citrate, vitamin B2, dimension life
Plain B6, folic acid, Vitwas E sieving, mixing, obtain premix；By stripped tuna extract, dietary fiber, premix, anhydrous
Lactose, crospovidone, silica mixing, add magnesium stearate mixing, tabletting, coating.
The present invention also provides a kind of anti-trioxypurine drug, including anti-trioxypurine composition provided by the invention and can pharmaceutically connect
The auxiliary material received.The anti-trioxypurine composition includes stripped tuna extract and dietary fiber, and dietary fiber is inulin and/or oligofructose.
Preferably, the mass ratio of stripped tuna extract and dietary fiber is (5~60): (5~70).
The present invention provides a kind of anti-trioxypurine composition and its preparations.The anti-trioxypurine composition includes stripped tuna extract and meals
Eat fiber.The present invention at least has one of following advantage:
1, the present invention is by after stripped tuna extract, dietary fiber composition use, in the case where reducing dose, anti-trioxypurine effect
It is more preferable instead；
2, citric acid, potassium citrate and sodium citrate can alkalize uric acid, promote uric acid excretion, so that uric acid level is reduced, from
And keep the anti-trioxypurine effect of the present composition more preferable；
3, vitamin B2, vitamin B6, folic acid and Vitwas E can effectively reduce serum uric acid level, to make this hair
The anti-trioxypurine effect of bright composition is more preferable.
Specific embodiment
The invention discloses a kind of anti-trioxypurine composition and its preparation, those skilled in the art can use for reference present disclosure,
It is suitably modified realization of process parameters.In particular, it should be pointed out that all similar substitutions and modifications carry out those skilled in the art
Say it is it will be apparent that they are considered as being included in the present invention.Method and application of the invention has passed through preferred embodiment
It is described, related personnel can obviously not depart from the content of present invention, in spirit and scope to method described herein and answer
With being modified or appropriate changes and combinations, carry out implementation and application the technology of the present invention.
Stripped tuna extract, vitamin, citric acid and its salt used in anti-trioxypurine composition and its preparation provided by the invention
Or auxiliary material is available on the market.
Instrument system: SUNRISE microplate reader, Austrian Tecan company；II centrifuge of LJX-, Shanghai medical analytical instrument
Factory；The desk-top water-bath constant temperature oscillator water-bath of SHZ88-1 type, Taicang light experimental analysis instrument plant；SIGMA centrifuge；
SHIMADZU Bl-220H electronic balance.
Below with reference to embodiment, the present invention is further explained:
The test of 1 anti-trioxypurine of embodiment
1, materials and methods
Experimental animal: selecting SPF grades of male SD rats, and 180 ± 10g of weight is mentioned by Guangdong Medical Lab Animal Center
For (credit number: SYXK (Guangdong) 2013-0002).
Test group: test is divided into blank control group, model group, Benzbromarone control group, the first control, the second control
Group, third control group, the first test group, the second test group, every group sets 10 rats.
Administration route: gastric infusion (it is consistent to intend route of administration with people's clinic).Administered volume: 10ml/kg.Administration time:
Therapeutic agent stomach-filling is given while modeling, the daily morning presses weight stomach-filling 1 time.The administration time limit: successive administration 28 days.
Drug is prepared: matching while using, weighs a certain amount of tested material and appropriate distilled water solution is added, and ultrasound stirs and evenly mixs,
It is spare.
Grouping and group situation are shown in Table 1:
The test of table 1 grouping and administrations
Test method:
Oteracil Potassium can inhibit uric acid as chemical inducer and decompose, and increases internal serum uric acid level, leads to internal blood
Uric acid level increases.This experimental selection Oteracil Potassium makees modeling agent, observes influence of the tested material to rat hyperuricemia.Blank
Oteracil Potassium solution is injected intraperitoneally in control group intraperitoneal injection of saline, remaining each group；Each administration group rat is while modeling
Give drug.
Testing index:
Experimental period is 28d, weighs within during which every 7 days that the weight of animals is primary, and every 7 days tail veins take blood primary, centrifugation, separation
Serum., urea nitrogen BUN, creatinine detecting serum UA, (uric acid reagent box is purchased from the magnificent scientific & technical corporation of middle life, lot number: 151221)
CRE。
As a result statistics and analysis:
The data of all experimental results are with mean ± standard deviationIt indicates, generally use variance analysis, variance is neat, meter
Calculate F value, F value < F0.05, conclusion: no significant difference between each group mean；F value >=F0.05, P≤0.05, with multiple experimental groups and
The comparative approach two-by-two of mean is counted between one control group；Variable appropriate is carried out to the data of abnormal or heterogeneity of variance
Conversion, after meeting normal state or variance and requiring together, is counted with the data after conversion；If being still not up to normal state after variable conversion
Or the purpose that variance is neat, it uses rank sum test instead and is counted.It is counted using variance analysis plus Q inspection.
2, test result
(1) ordinary circumstance is observed
Whole rats are in good condition before test.Compared with Normal group, model group rats hair owes smooth outer, outside
It sees sign, behavioral activity, fecal character etc. and has no notable difference.Compared with model control group, appearance signs, behavioral activities,
Fecal character etc. has no notable difference.
(2) to the influence of the weight of animals
During 28d is administered, compared with normal group, model group rats the 7th, 14,21,28d weight have no notable difference (P >
0.05)；Compared with model group, each administration group rat the 7th, 14,21,28d weight have no that notable difference is shown in Table 2.
Table 2 be administered 28d during each group rat body weight variation (n=10,g)
| Group | Before administration | 7d | 14d | 21d | 28d |
| Normal group | 219.70±10.52 | 268.53±10.86 | 313.65±18.69 | 342.70±23.34 | 374.81±32.20 |
| Model group | 224.56±11.33 | 268.12±12.32 | 309.43±17.66 | 338.42±21.00 | 366.62±24.70 |
| Benzbromarone group | 225.13±11.03 | 265.43±10.28 | 301.64±12.40 | 330.96±19.89 | 356.14±25.72 |
| First control group | 210.24±12.89 | 270.19±11.26 | 310.33±16.70 | 337.56±21.90 | 366.17±26.29 |
| Second control group | 217.45±12.23 | 259.87±10.53 | 312.35±15.88 | 336.62±22.45 | 372.43±25.91 |
| Third control group | 220.67±12.56 | 262.56±9.99 | 307.28±16.43 | 342.28±25.58 | 360.33±24.18 |
| First test group | 219.07±13.54 | 270.28±10.37 | 311.45±14.40 | 340.83±20.65 | 365.84±27.78 |
| Second test group | 226.91±10.65 | 268.73±10.46 | 312.78±15.19 | 343.36±24.38 | 370.32±26.55 |
Note: with normal group than * P < 0.05, * * P < 0.01；With model group ratioΔP < 0.05,ΔΔP < 0.01
(3) to the influence of animal blood serum uric acid (UA) level
Compared with normal group, the 14th, 21, the horizontal significant raising (P < 0.05 or P < 0.01) of 28d model group serum UA.With mould
Type group ratio, administration the 14th, 21,28d Benzbromarone group serum UA level significant decrease (P < 0.05 or P < 0.01)；Be administered the 14th,
21,28d, the first control group, the second control group, third control group serum UA level have no and are substantially reduced (P > 0.05)；Test group
14d serum UA level be administered after administration have no and be substantially reduced (P > 0.05), 21d, 28d serum UA level be substantially reduced (P <
0.05).It is shown in Table 3.
Table 3 be administered 28d during each group rat UA (n=10,μm ol/l) horizontal variation
| Group | Before administration | 7d | 14d | 21d | 28d |
| Normal group | 60.78±22.01 | 65.21±24.38 | 59.89±17.95 | 78.78±24.68 | 90.92±26.95 |
| Model group | 55.42±20.23 | 68.32±20.61 | 100.67±18.90** | 104.00±21.27* | 150.11±44.92** |
| Benzbromarone group | 56.78±22.32 | 66.11±25.71 | 74.44±14.48ΔΔ | 67.03±32.49ΔΔ | 80.44±21.84ΔΔ |
| First control group | 55.33±21.16 | 68.19±26.54 | 88.23±20.91 | 90.43±25.67 | 143.34±38.56 |
| Second control group | 56.32±21.57 | 70.89±24.98 | 95.72±18.12 | 98.86±24.42 | 145.56±33.18 |
| Third control group | 57.26±26.70 | 72.23±26.10 | 94.38±19.65 | 97.54±23.88 | 140.24±42.12 |
| First test group | 58.99±26.66 | 61.99±24.41 | 86.32±28.45 | 80.05±16.25Δ | 100.88±32.55Δ |
| Second test group | 60.16±22.78 | 60.46±28.60 | 85.55±20.76 | 79.54±18.46Δ | 101.34±30.58Δ |
Note: with normal group than * P < 0.05, * * P < 0.01；With model group ratioΔP < 0.05,ΔΔP < 0.01
By above-mentioned test result it is found that with stripped tuna extract is individually given, and individually give inulin or oligofructose phase
Compare, the dosage of stripped tuna extract, dietary fiber is greatly reduced, and after being applied in combination by a certain percentage, can produce more preferable
Anti-trioxypurine effect.
The test of 2 anti-trioxypurine of embodiment
1, materials and methods
Experimental animal: selecting SPF grades of male SD rats, and 180 ± 10g of weight is mentioned by Guangdong Medical Lab Animal Center
For (credit number: SYXK (Guangdong) 2013-0002).
Test group: test is divided into blank control group, model group, Benzbromarone control group, the first control, the second control
Group, third control group, the first test group, the second test group, every group sets 10 rats.
Administration route: gastric infusion (it is consistent to intend route of administration with people's clinic).Administered volume: 10ml/kg.Administration time:
Therapeutic agent stomach-filling is given while modeling, the daily morning presses weight stomach-filling 1 time.The administration time limit: successive administration 28 days.
Drug is prepared: matching while using, weighs a certain amount of tested material and appropriate distilled water solution is added, and ultrasound stirs and evenly mixs,
It is spare.
Grouping and group situation are shown in Table 4:
The test of table 4 grouping and administrations
Test method:
Oteracil Potassium can inhibit uric acid as chemical inducer and decompose, and increases internal serum uric acid level, leads to internal blood
Uric acid level increases.This experimental selection Oteracil Potassium makees modeling agent, observes influence of the tested material to rat hyperuricemia.Blank
Oteracil Potassium solution is injected intraperitoneally in control group intraperitoneal injection of saline, remaining each group；Each administration group rat is while modeling
Give drug.
Testing index:
Experimental period is 28d, weighs within during which every 7 days that the weight of animals is primary, and every 7 days tail veins take blood primary, centrifugation, separation
Serum., urea nitrogen BUN, creatinine detecting serum UA, (uric acid reagent box is purchased from the magnificent scientific & technical corporation of middle life, lot number: 151221)
CRE。
As a result statistics and analysis:
The data of all experimental results are with mean ± standard deviationIt indicates, generally use variance analysis, variance is neat, meter
Calculate F value, F value < F0.05, conclusion: no significant difference between each group mean；F value >=F0.05, P≤0.05, with multiple experimental groups and
The comparative approach two-by-two of mean is counted between one control group；Variable appropriate is carried out to the data of abnormal or heterogeneity of variance
Conversion, after meeting normal state or variance and requiring together, is counted with the data after conversion；If being still not up to normal state after variable conversion
Or the purpose that variance is neat, it uses rank sum test instead and is counted.It is counted using variance analysis plus Q inspection.
2, test result
(1) ordinary circumstance is observed
Whole rats are in good condition before test.Compared with Normal group, model group rats hair owes smooth outer, outside
It sees sign, behavioral activity, fecal character etc. and has no notable difference.Compared with model control group, appearance signs, behavioral activities,
Fecal character etc. has no notable difference.
(2) to the influence of the weight of animals
During 28d is administered, compared with normal group, model group rats the 7th, 14,21,28d weight have no notable difference (P >
0.05)；Compared with model group, each administration group rat the 7th, 14,21,28d weight have no that notable difference is shown in Table 5.
Table 5 be administered 28d during each group rat body weight variation (n=10,g)
| Group | Before administration | 7d | 14d | 21d | 28d |
| Normal group | 219.70±10.52 | 268.53±10.86 | 313.65±18.69 | 342.70±23.34 | 374.81±32.20 |
| Model group | 224.56±11.33 | 268.12±12.32 | 309.43±17.66 | 338.42±21.00 | 366.62±24.70 |
| Benzbromarone group | 225.131±1.03 | 265.43±10.28 | 301.64±12.40 | 330.96±13.58 | 356.77±15.72 |
| First control group | 210.27±10.23 | 259.12±11.54 | 311.19±15.46 | 335.12±23.45 | 366.834±24.08 |
| Second control group | 218.93±12.24 | 260.43±12.78 | 309.28±14.89 | 340.78±21.22 | 368.46±22.30 |
| Third control group | 220.46±13.05 | 264.58±10.65 | 305.34±15.65 | 332.66±24.56 | 372.27±23.45 |
| First test group | 223.55±11.05 | 268.29±13.22 | 308.24±16.23 | 336.43±20.78 | 369.90±27.07 |
| Second test group | 226.07±13.52 | 270.33±12.12 | 320.56±17.56 | 348.26±26.55 | 373.03±23.56 |
Note: with normal group than * P < 0.05, * * P < 0.01；With model group ratioΔP < 0.05,ΔΔP < 0.01
(3) to the influence of animal blood serum uric acid (UA) level
Compared with normal group, the 14th, 21, the horizontal significant raising (P < 0.05 or P < 0.01) of 28d model group serum UA.With mould
Type group ratio, administration the 14th, 21,28d Benzbromarone group serum UA level significant decrease (P < 0.05 or P < 0.01)；Be administered the 14th,
21,28d, the first control group, the second control group, third control group serum UA level have no and are substantially reduced (P > 0.05)；Test group
After administration administration the 14th, 21d serum UA level have no and be substantially reduced (P > 0.05), 28d serum UA level be substantially reduced (P <
0.05)。
It is shown in Table 6.
Table 6 be administered 28d during each group rat UA (n=10,μm ol/l) horizontal variation
| Group | Before administration | 7d | 14d | 21d | 28d |
| Normal group | 60.78±22.01 | 65.21±24.38 | 59.89±17.95 | 78.78±24.68 | 90.92±26.95 |
| Model group | 55.42±20.23 | 68.32±20.61 | 100.67±18.90** | 104.00±21.27* | 150.11±44.92** |
| Benzbromarone group | 56.78±22.32 | 66.11±25.71 | 74.44±14.48ΔΔ | 67.03±32.49ΔΔ | 80.44±21.84ΔΔ |
| First control group | 53.86±23.45 | 62.56±24.87 | 83.32±29.45 | 89.99±26.62 | 123.454±40.19 |
| Second control group | 57.83±24.95 | 69.54±23.32 | 97.65±20.19 | 95.54±23.76 | 140.28±33.68 |
| Third control group | 58.02±25.32 | 70.19±24.58 | 98.46±22.54 | 98.19±25.73 | 138.76±38.54 |
| First test group | 52.33±22.16 | 60.55±22.21 | 87.78±23.31 | 85.55±28.55 | 97.34±33.65Δ |
| Second test group | 53.78±25.53 | 61.76±25.90 | 88.66±25.71 | 88.98±27.89 | 96.54±32.48Δ |
Note: with normal group than * P < 0.05, * * P < 0.01；With model group ratioΔP < 0.05,ΔΔP < 0.01
By above-mentioned test result it is found that with stripped tuna extract is individually given, and individually give inulin or oligofructose phase
Compare, the dosage of stripped tuna extract, dietary fiber is greatly reduced, and after being applied in combination by a certain percentage, can produce more preferable
Anti-trioxypurine effect.
The test of 3 anti-trioxypurine of embodiment
1, materials and methods
Experimental animal: selecting SPF grades of male SD rats, and 180 ± 10g of weight is mentioned by Guangdong Medical Lab Animal Center
For (credit number: SYXK (Guangdong) 2013-0002).
Test group: test is divided into blank control group, model group, Benzbromarone control group, the first control group~six couple
According to group, the first test group~the 6th test group, every group sets 10 rats.
Administration route: gastric infusion (it is consistent to intend route of administration with people's clinic).Administered volume: 1.5ml/100g.When administration
Between: therapeutic agent stomach-filling is given while modeling, the daily morning presses weight stomach-filling 1 time.The administration time limit: successive administration 28 days.
Drug is prepared: matching while using, weighs a certain amount of tested material and appropriate distilled water solution is added, and ultrasound stirs and evenly mixs,
It is spare.
Grouping and group situation are shown in Table 7:
The test of table 7 grouping and administrations
Test method:
Oteracil Potassium can inhibit uric acid as chemical inducer and decompose, and increases internal serum uric acid level, leads to internal blood
Uric acid level increases.This experimental selection Oteracil Potassium makees modeling agent, observes influence of the tested material to rat hyperuricemia.Normally
Oteracil Potassium solution is injected intraperitoneally in group intraperitoneal injection of saline, remaining each group；Each administration group rat is given while modeling
Drug.
Testing index:
Experimental period is 28d, weighs within during which every 7 days that the weight of animals is primary, and every 7 days tail veins take blood primary, centrifugation, separation
Serum., urea nitrogen BUN, creatinine detecting serum UA, (uric acid reagent box is purchased from the magnificent scientific & technical corporation of middle life, lot number: 151221)
CRE。
As a result statistics and analysis:
As a result it is indicated with means standard deviation；Weight and Biochemical Indices In Serum use 17.0 statistical software of SPSS to calculate respectively
Every group of average and standard deviation and ANOVA variance analysis is carried out out, P < 0.05 is significant difference.
2, test result
(1) ordinary circumstance is observed
Whole rats are in good condition before test.Compared with Normal group, model group rats hair owes smooth outer, outside
It sees sign, behavioral activity, fecal character etc. and has no notable difference.Compared with model control group, appearance signs, behavioral activities,
Fecal character etc. has no notable difference.
(2) to the influence of the weight of animals
During 28d is administered, compared with normal group, model group rats the 7th, 14,21,28d weight have no notable difference (P >
0.05)；Compared with model group, each administration group rat the 7th, 14,21,28d weight have no that notable difference is shown in Table 8.
Table 8 be administered 28d during each group rat body weight variation (n=10,g)
| Group | Before administration | 7d | 14d | 21d | 28d |
| Normal group | 219.70±10.52 | 268.53±10.86 | 313.65±18.69 | 342.70±23.34 | 374.81±32.20 |
| Model group | 224.56±11.33 | 268.12±12.32 | 309.43±17.66 | 338.42±21.00 | 366.62±24.70 |
| Benzbromarone group | 225.131±1.03 | 265.43±10.28 | 301.64±12.40 | 330.96±13.58 | 356.14±15.72 |
| First control group | 222.06±10.90 | 269.46±13.32 | 303.46±20.54 | 332.31±27.52 | 355.63±32.09 |
| Second control group | 226.65±9.56 | 270.46±11.52 | 310.53±19.87 | 337.45±26.32 | 368.72±28.85 |
| Third control group | 222.06±10.90 | 263.32±15.53 | 307.33±12.38 | 342.78±20.33 | 370.85±27.79 |
| 4th control group | 230.06±10.23 | 264.64±11.03 | 304.94±13.56 | 332.51±14.36 | 355.58±15.46 |
| 5th control group | 229.422±10.23 | 260.90±12.25 | 298.64±17.12 | 339.89±18.87 | 368.18±20.72 |
| 6th control group | 224.01±12.98 | 257.56±12.45 | 299.44±12.70 | 331.32±26.61 | 345.48±27.72 |
| First test group | 223.31±9.87 | 267.35±10.30 | 305.57±10.65 | 339.41±14.90 | 364.68±17.58 |
| Second test group | 228.32±10.03 | 260.76±11.32 | 298.42±13.40 | 333.92±12.00 | 368.21±11.19 |
| Third test group | 229.68±12.24 | 256.72±11.50 | 301.99±14.21 | 334.78±18.73 | 360.42±20.05 |
| 4th test group | 227.32±10.28 | 262.78±12.25 | 300.54±157.12 | 338.68±15.65 | 353.818±18.56 |
| 5th test group | 228.86±10.42 | 259.56±12.45 | 297.32±14.68 | 341.45±16.64 | 344.44±22.12 |
| 6th test group | 227.93±9.98 | 256.72±11.50 | 304.99±15.32 | 344.78±18.37 | 3540.87±16.05 |
Note: with normal group than * P < 0.05, * * P < 0.01；With model group ratioΔP < 0.05,ΔΔP < 0.01
(3) to the influence of animal blood serum uric acid (UA) level
Table 9 be administered 28d during each group rat UA (n=10,μm ol/l) horizontal variation
Note: with normal group than * P < 0.05, * * P < 0.01；With model group ratioΔP < 0.05,ΔΔP < 0.01
Compared with normal group, the 14th, 21, the horizontal significant raising (P < 0.05 or P < 0.01) of 28d model group serum UA.With mould
Type group ratio, administration the 14th, 21,28d Benzbromarone group serum UA level significant decrease (P < 0.05 or P < 0.01)；Be administered the 14th,
21,28d, the first control group~the 6th control group serum UA level have no and are substantially reduced (P > 0.05)；First, second test group
The 14th, 21,28d rat blood serum UA level significant decrease (P < 0.05) are administered；The 14th, 21d blood is administered after the administration of third test group
Clear UA level has no that being substantially reduced (P > 0.05) 28d serum UA level is substantially reduced (P < 0.05)；Four, the five, the 6th examinations
Group administration the 14th, 21,28d rat blood serum UA level significant decrease (P < 0.05 or P < 0.01) are tested, is shown in Table 2.
By above-mentioned test result it is found that with stripped tuna extract is individually given, and individually gives dietary fiber and compare, it will
The dosage of stripped tuna extract and dietary fiber greatly reduces, and after being applied in combination by a certain percentage, can produce preferably drop urine
Sour effect.Meanwhile vitamin B is added2, vitamin B6, folic acid and Vitwas E, citric acid, potassium citrate and citric acid
Sodium can play the role of certain auxiliary anti-trioxypurine.
The preparation of 4 anti-trioxypurine troche of health products of embodiment
Tablet formulation are as follows:
By anhydrous citric acid, potassium citrate, sodium citrate, vitamin B2, vitamin B6, folic acid, Vitwas E mistake
Sieve, mixing obtain premix；By stripped tuna extract, inulin, premix, Lactis Anhydrous (vertical compression type), crospovidone, dioxy
SiClx mixing adds magnesium stearate mixing, tabletting, coating.
The preparation of 5 anti-trioxypurine troche of health products of embodiment
Tablet formulation are as follows:
By anhydrous citric acid, potassium citrate, sodium citrate, vitamin B2, vitamin B6, folic acid, Vitwas E mistake
Sieve, mixing obtain premix；By stripped tuna extract, oligofructose, premix, Lactis Anhydrous (vertical compression type), crospovidone,
Silica mixing adds magnesium stearate mixing, tabletting, coating.
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications are also answered
It is considered as protection scope of the present invention.
Claims (9)
1. a kind of anti-trioxypurine composition, which is characterized in that be made of stripped tuna extract and dietary fiber；
The dietary fiber is inulin and/or oligofructose；
The mass ratio of the stripped tuna extract and the dietary fiber is (1~12): (1~14).
2. anti-trioxypurine composition according to claim 1, which is characterized in that the stripped tuna extract and the dietary fiber
Mass ratio be 1:5.
3. a kind of anti-trioxypurine composition, which is characterized in that the anti-trioxypurine composition is given birth to by stripped tuna extract, dietary fiber, dimension
Plain B, Vitwas E, citric acid, citrate composition, the dietary fiber are inulin and/or oligofructose, the oceanic bonito
The mass ratio of fish extracts and the dietary fiber is (1~12): (1~14).
4. anti-trioxypurine composition according to claim 3, which is characterized in that the vitamin B is vitamin B2, vitamin
B6Or the above mixture of one or both of folic acid, the citrate are sodium citrate and/or potassium citrate.
5. anti-trioxypurine composition according to claim 4, which is characterized in that the stripped tuna extract, the dietary fiber,
The vitamin B2, the vitamin B6, the folic acid, the Vitwas E, the citric acid, the sodium citrate with
The mass ratio of the potassium citrate is (5~60): (5~70): (0.1~10): (0.1~10): (0.001~0.01): (0.5
~10): (0.1~10): (1~20): (1~20).
6. a kind of anti-trioxypurine health care product, which is characterized in that including the anti-trioxypurine composition as described in any one of claims 1 to 5
With auxiliary material acceptable in bromatology.
7. anti-trioxypurine health care product according to claim 6, which is characterized in that the dosage form of the anti-trioxypurine health care product is piece
Agent, capsule, pulvis or granule.
8. anti-trioxypurine health care product according to claim 6, which is characterized in that acceptable auxiliary material is to fill out in the bromatology
Fill the mixture of one or both of agent, disintegrating agent, adhesive or lubricant or more.
9. a kind of anti-trioxypurine drug, which is characterized in that including as described in any one of claims 1 to 5 anti-trioxypurine composition and
Pharmaceutically acceptable auxiliary material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510925081.0A CN105380962B (en) | 2015-12-11 | 2015-12-11 | A kind of anti-trioxypurine composition and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510925081.0A CN105380962B (en) | 2015-12-11 | 2015-12-11 | A kind of anti-trioxypurine composition and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105380962A CN105380962A (en) | 2016-03-09 |
| CN105380962B true CN105380962B (en) | 2019-02-22 |
Family
ID=55414138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510925081.0A Active CN105380962B (en) | 2015-12-11 | 2015-12-11 | A kind of anti-trioxypurine composition and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105380962B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106420758B (en) * | 2016-08-31 | 2018-09-11 | 昆明理工大学 | A method of utilizing long-term hyperuricemia inducing mouse Gout Model |
| CN109430667A (en) * | 2018-10-19 | 2019-03-08 | 张东祥 | A kind of composition and solid beverage with anti-trioxypurine effect |
| CN110051002A (en) * | 2019-04-28 | 2019-07-26 | 杭州泽健医药科技有限公司 | A kind of pharmaceutical composition with anti-trioxypurine effect |
| CN110038119A (en) * | 2019-04-28 | 2019-07-23 | 杭州泽健医药科技有限公司 | A kind of pharmaceutical composition with anti-trioxypurine and antifatigue effect |
| CN111704650B (en) * | 2020-06-29 | 2021-11-23 | 中食都庆（山东）生物技术有限公司 | Polypeptide with uric acid reducing effect, composition, compound preparation, preparation method and application |
| CN115104734A (en) * | 2022-07-19 | 2022-09-27 | 中山市嘉信医疗器械有限公司 | Uric acid-reducing health food and preparation method thereof |
| CN115177634A (en) * | 2022-07-26 | 2022-10-14 | 武汉英纽林生物科技有限公司 | Anti-gout composition and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102077933A (en) * | 2010-09-20 | 2011-06-01 | 王强 | Special dietary seafood special for hyperuricemia patients |
| CN104784210A (en) * | 2015-04-30 | 2015-07-22 | 无限极（中国）有限公司 | Preparation method and application of skipjack extract with uric acid reduction effect |
| CN105029447A (en) * | 2015-08-11 | 2015-11-11 | 湖南科尔生物技术有限公司 | Sea-fish oligopeptide powder containing activated probiotics |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2632577B2 (en) * | 1989-05-29 | 1997-07-23 | 日本化薬株式会社 | Hyperuricemia improving agent and food for improvement |
-
2015
- 2015-12-11 CN CN201510925081.0A patent/CN105380962B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102077933A (en) * | 2010-09-20 | 2011-06-01 | 王强 | Special dietary seafood special for hyperuricemia patients |
| CN104784210A (en) * | 2015-04-30 | 2015-07-22 | 无限极（中国）有限公司 | Preparation method and application of skipjack extract with uric acid reduction effect |
| CN105029447A (en) * | 2015-08-11 | 2015-11-11 | 湖南科尔生物技术有限公司 | Sea-fish oligopeptide powder containing activated probiotics |
Non-Patent Citations (3)
| Title |
|---|
| "METABOLISM OF L-HISTIDINE, CARNOSINE, AND ANSERINE";HIROKI ABE et al.,;《Physiological Zoology》;19991231;第59卷(第4期);第439-450 |
| "痛风患者降尿酸有了安全新方法";郭文等;《长寿》;20091231(第9期);第35页 |
| "酸泰宁有什么副作用";匿名;《https://zhidao.baidu.com/question/1768613826778860060.html》;20151002 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105380962A (en) | 2016-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105380962B (en) | A kind of anti-trioxypurine composition and its preparation | |
| CN105395577B (en) | A kind of anti-trioxypurine composition and its preparation | |
| CN102670864B (en) | Medicine composition with antioxidant function for treating cardiovascular and cerebrovascular diseases and sugar diabetes | |
| CN101983064B (en) | Absorbent ingestible agents and associated methods of manufacture and use | |
| CN101180062A (en) | Compound preparation for treating diabetes mellitus | |
| CN101239069A (en) | Application of compound capable of supplying active methyl or engaging in methyl migration | |
| CN105073129A (en) | Pharmaceutical compositions for oral treatment of diabetes | |
| CN109122859A (en) | Anti-trioxypurine composition and the preparation method and application thereof | |
| CN113398144A (en) | Application of nucleotide mixture in preparation of preparation for preventing or relieving sarcopenia of old people | |
| UA124965C2 (en) | Composition comprising a pentose and polyphenolic compound | |
| CN101912407B (en) | Weight-reducing and lipid-lowering composition | |
| JP2010111646A (en) | Treating agent for ulcerative colitis | |
| KR101989739B1 (en) | Composition for preventing or treating diabetes mellitus comprising Rorippa globosa extracts | |
| CN102342949B (en) | Application of phlorhizin in preparation of drug for treating hyperuricemia | |
| CN105012294B (en) | New application of the ellagic acid compounds in treatment antihyperuricemic disease drug is prepared | |
| CN107744571A (en) | A kind of pharmaceutical composition for improving blood vessel endothelium dysfunction and its production and use | |
| CA2861661C (en) | Improved synergistic anti-diabetic compositions | |
| CN105982921A (en) | Composition for treating gout and application thereof | |
| CN104127594A (en) | Phytoextraction composition applied to prevention and control of diabetes | |
| CN104095868B (en) | A kind of pharmaceutical composition and pharmaceutical applications thereof improving sugar tolerance | |
| US20050003027A1 (en) | Chemical composition and method to bind fat, enhance metabolization, and aid digestion | |
| CN104605344A (en) | Health food for enhancing immunity and preparation method of health food | |
| CN103989752A (en) | Pharmaceutical composition used for preventing and treating diabetes mellitus combined with hypertension | |
| CN103656161B (en) | A kind of Chinese medicine composition and its production and use | |
| US11744870B2 (en) | Traditional Chinese medicine composition for treating metabolic syndrome and preparations thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |